Wall Street Week Ahead: Investors look beyond drug makers as hunt for Covid-19 treatment heats up
By David Randall NEW YORK (Reuters) - Investors are diversifying bets in the healthcare sector, as the rush to develop treatments for Covid-19 has driven up prices for some pharmaceutical stocks. A record 48% of fund managers are overweight healthcare stocks, a BofA survey showed, and the S&P 500 healthcare sector is up nearly 34% since its March low. Hopes for a treatment have also sparked outsize rallies in the shares of companies such as Moderna and Inovio Pharmaceutcials, up 253% and 327% since the start of the year, respectively, as of Friday's close
COVID-19 treatment heats up" src="https://images.firstpost.com/wp-content/uploads/reuters/05-2020/23/2020-05-22T113849Z_1_LYNXMPEG4L122_RTROPTP_2_USA-CFTC-PENALTIES.jpg" alt="Wall Street Week Ahead Investors look beyond drug makers as hunt for Covid19 treatment heats up" width="300" height="225" />
By David Randall
NEW YORK (Reuters) - Investors are diversifying bets in the healthcare sector, as the rush to develop treatments for COVID-19 has driven up prices for some pharmaceutical stocks.
A record 48% of fund managers are overweight healthcare stocks, a BofA survey showed, and the S&P 500 healthcare sector is up nearly 34% since its March low. Hopes for a treatment have also sparked outsize rallies in the shares of companies such as Moderna and Inovio Pharmaceutcials, up 253% and 327% since the start of the year, respectively, as of Friday's close.
In recent weeks, news of potential treatments or vaccines to fight the pandemic have occasionally fueled swings in broader markets.
Yet some fund managers believe lasting profits may be elusive for vaccine-makers, leading them to seek corners of the healthcare sector that could see longer-term benefits from the fight against coronavirus .
Large pharmaceutical companies such as Johnson & Johnson
"There's the question of 'Does anyone really make a lot of money on this?," said Larry Cordisco, co-portfolio manager of the Osterweis Fund.
Signs of progress on potential treatments could bolster the case for a quicker economic recovery and further fuel the rally that has boosted the S&P 500 around 30% from its late March lows. In the next two weeks, Gilead Sciences is expected to announce results of clinical studies of its potential coronavirus treatment remdesivir for patients with moderate symptoms of COVID-19 . Pfizer has said it expects to release safety data for initial human testing of experimental vaccine by the end of May.
Cordisco is looking further afield. One of the companies he owns is medical device maker Danaher Corp
"If you're looking for where the profits might be in the chain, it’s somebody like that who is going to benefit. They can cash in the whole way," Cordisco said.
Alessandro Valentini, portfolio manager at Causeway Capital Management, said his firm is looking for value opportunities as the healthcare sector becomes more expensive, trading now at 22.9 times trailing earnings, slightly more than the 21.9 multiple of the S&P 500 index as a whole.
He is staying away from potential vaccine producers in favor of companies such as Takeda Pharmaceutical Co Ltd <4502.T>. Japan's largest pharmaceutical company said this month it could start clinical trials as early as July for a COVID-19 treatment based on antibodies from blood of recovered patients.
"This is a company that will be part of the solution and can buy a world class business for a significant discount to what we think the fair value is," Valentini said. Its shares are down nearly 6.5% for the year to date.
Mike Caldwell, a portfolio manager of the Driehaus Event Driven Fund, said his fund is focusing on supply chains of vaccine production rather than the drug companies themselves.
He is betting on companies such as Roche Holding
He is also bullish on smaller companies such as Luminex Corp
"With so many players who have meaningful resources, it's hard to predict what the ultimate market share of any one approach will be," he said.
(Reporting by David Randall; Editing by Ira Iosebashvili and David Gregorio)
This story has not been edited by Firstpost staff and is generated by auto-feed.
(In first paragraph, fixes hyperlink to story) By Katanga Johnson WASHINGTON (Reuters) -U.S.
By Ben Klayman DETROIT (Reuters) - General Motors Co's marketing and promotional spending will return to normal levels after the COVID-19 pandemic caused that budget to drop last year, the U.S. automaker's top marketing officer said on Monday. "What we went through in the pandemic was certainly severe and we should be moving back up to our normalized levels," GM Chief Marketing Officer Deborah Wahl said in an online appearance at a Reuters Events conference.
By Nandita Bose WASHINGTON (Reuters) - U.S. President Joe Biden will urge Congress to invest $50 billion in semiconductor manufacturing and research when he meets with top executives from nearly 20 major companies on Monday about the global chips shortage that has roiled the automotive industry and technology firms. The push is part of his broader focus on rebuilding U.S